Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

ABSTRACT: Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

DISEASE(S): Carcinoma,Cervical Cancer,Melanoma,Glioblastoma,Colorectal Cancer,Non Small Cell Lung Cancer,Mesothelioma,Breast Cancer,Pancreatic Ductal Adenocarcinoma,Ovarian Cancer,Squamous Cell Carcinoma Of Head And Neck,Endocervical Cancer,Gastric Cancer,Esophageal Cancer,Renal Cell Carcinoma,Cholangiocarcinoma

PROVIDER: 2379568 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Project description:The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.

| 2361054 | ecrin-mdr-crc

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Project description:Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

| 2402815 | ecrin-mdr-crc

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Project description:Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

| 2717427 | ecrin-mdr-crc

Immuno-Transcriptomic Profiling Identifies Actionable Alterations in Pediatric Solid Malignancies

Project description:Immuno-Transcriptomic Profiling Identifies Actionable Alterations in Pediatric Solid Malignancies

2021-12-07 | PXD017130 | Pride

A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Project description:This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

| 2297842 | ecrin-mdr-crc

Paired tumour biopsy gene expression data from patients with solid tumours, before and after combination treatment.

Project description:Gene expression quantification of PanCancer IO genes from paired tumour biopsies from 24 patients with pan-cancer solid tumours, before and after treatment with MTL-CEBPA and pembrolizumab.

2024-10-23 | GSE233860 | GEO

Expression of Pembrolizumab-treated tumors

Project description:Expression profiling of 12 Pembrolizumab-treated tumors with CancerImmune Panel

2023-10-01 | E-MTAB-8288 | biostudies-arrayexpress

An Integrative Proteome-Based Pharmacologic Characterization and Therapeutic Strategy Exploration of SAHA in Solid Malignancies

Project description:An Integrative Proteome-Based Pharmacologic Characterization and Therapeutic Strategy Exploration of SAHA in Solid Malignancies.

2021-12-07 | PXD030220 |